Evidence map›Paper›PMID 41962897›Full record

ArticleChest2026

Imaging-Based Pulmonary Hypertension Phenotypes in Connective Tissue Disease-Related Interstitial Lung Disease.

Sarah L Khan, Kevin J Psoter, Cheng Ting Lin, Aparna Balasubramanian, Catherine E Simpson, Matthew R Lammi, Tijana Tuhy, Rachel L Damico, Todd M Kolb, Paul M Hassoun and 2 more

Abstract read
In one paragraph

Article in Chest, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sarah L KhanDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Kevin J PsoterDivision of General Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD.
Cheng Ting LinDepartment of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD.
Aparna BalasubramanianDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Catherine E SimpsonDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Matthew R LammiDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Tijana TuhyDepartment of Pulmonary and Critical Care Medicine, The Oregon Clinic, Portland, OR.
Rachel L DamicoDepartment of Pulmonary, Critical Care, and Sleep Medicine, University of Miami Miller School of Medicine, Miami, FL.
Todd M KolbDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Paul M HassounDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Sonye K DanoffDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Stephen C MathaiDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD. Electronic address: smathai4@jhmi.edu.

Funding

MULTIDISCIPLINARY TRAINING PROGRAM IN LUNG DISEASEST32HL007534 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Nadia N Hansel, Larissa A. Shimoda · 1985 to 2026
$28.3M
Distinguishing Phenotypes of Pulmonary Hypertension in Patients with Connective Tissue Disease-related Interstitial Lung DiseaseF32HL170482 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI KHAN, SARAH · 2023 to 2024
$185k
NHLBI NIH HHS F32 HL170482NHLBI NIH HHS T32 HL007534
6 · The paper itself

Abstract

backgroundPatients with connective tissue disease-related interstitial lung disease (CTD-ILD) may demonstrate pulmonary hypertension (PH) through pulmonary parenchymal destruction and chronic hypoxia or via endovascular changes driven by the underlying autoimmunity. Distinguishing which process-parenchymal or vascular-is the primary cause has important therapeutic and prognostic implications. RESEARCH QUESTION: Can chest imaging be used to classify patients with CTD-ILD and PH systematically as having a parenchymal or vascular PH phenotype? STUDY DESIGN AND

methodsChest CT imaging was used to classify 275 adult patients with CTD-ILD and PH in the Johns Hopkins ILD and PH registries as having a parenchymal or vascular PH phenotype. CT imaging-based PH phenotypes were determined using a validated ILD severity staging tool that involves visual inspection of the percentage of lung affected by CTD-ILD. The primary outcome was time to clinical worsening (defined as a composite of physiologic worsening, hospital admission for a pulmonary or cardiac diagnosis, lung transplantation, or death), which was compared between the 2 phenotypes. Secondary outcomes included comparisons of baseline cardiopulmonary testing results, time to physiologic worsening, time to hospital admission, and time to lung transplantation or death. Clinical outcomes also were compared between the CT imaging-based PH phenotypes and the conventional World Symposium on Pulmonary Hypertension (WSPH) group classifications.

resultsPatients with CTD-ILD and the parenchymal PH phenotype were 1.76 times more likely to experience clinical worsening than those with the vascular phenotype. They were also more likely to experience physiologic worsening, hospitalization, and lung transplantation or death. CT imaging-based PH phenotypes were associated more closely with clinical outcomes than the WSPH group classifications.

interpretationOur research shows that patients with CTD-ILD and the parenchymal PH phenotype have worse clinical outcomes than those with the vascular PH phenotype. CT imaging-based PH phenotypes may characterize patients' risk of clinical worsening more reliably than the WSPH groups.

Indexed as

Connective Tissue DiseasesHypertension, PulmonaryLung Diseases, InterstitialTomography, X-Ray ComputedDisease ProgressionFemaleHumansMaleMiddle AgedPhenotypePrognosisclinical outcomesCTinterstitial lung diseasephenotypingpulmonary hypertension

Identifiers

PMID41962897
PMCPMC13494247

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.